{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:47:02Z","timestamp":1793216822147,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.ejps.2010.07.015","type":"journal-article","created":{"date-parts":[[2010,8,4]],"date-time":"2010-08-04T09:15:31Z","timestamp":1280913331000},"page":"458-463","source":"Crossref","is-referenced-by-count":150,"title":["Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass"],"prefix":"10.1016","volume":"41","author":[{"given":"Deise Raquel","family":"Barpe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Dornelles","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Eduardo","family":"Froehlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2010.07.015_bib0005","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/jnci\/94.24.1883","article-title":"Role of body surface area in dosing of investigational anticancer agents in adults, 1991\u20132001","volume":"94","author":"Baker","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejps.2010.07.015_bib0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1053>3.0.CO;2-T","article-title":"Overweight as an avoidable cause of cancer in Europe","volume":"91","author":"Bergstrom","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejps.2010.07.015_bib0015","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003495-199447020-00002","article-title":"Anthracycline antibiotics in cancer therapy: focus on drug resistance","volume":"47","author":"Booser","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2010.07.015_bib0020","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1006\/abio.1998.2943","article-title":"Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography","volume":"266","author":"Bruijn","year":"1999","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejps.2010.07.015_bib0025","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","article-title":"Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer","volume":"90","author":"Budman","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejps.2010.07.015_bib0030","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults","volume":"348","author":"Calle","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2010.07.015_bib0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1570-0232(02)00395-1","article-title":"Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet\u2013visible high-performance liquid chromatography","volume":"779","author":"Chin","year":"2002","journal-title":"J. Chromatogr. B: Analyt. Technol. Biomed. Life. Sci."},{"key":"10.1016\/j.ejps.2010.07.015_bib0040","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/jnci\/djg060","article-title":"Tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer","volume":"19","author":"Dignam","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejps.2010.07.015_bib0045","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JOP.0832001","article-title":"Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey","volume":"4","author":"Field","year":"2008","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.ejps.2010.07.015_bib0050","series-title":"Guidance for Industry: Bioanalytical Method Validation","author":"Food and Drug Administration","year":"2001"},{"key":"10.1016\/j.ejps.2010.07.015_bib0055","first-page":"3417","article-title":"Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols","volume":"43","author":"Greene","year":"1983","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2010.07.015_bib0060","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.1998.16.7.2299","article-title":"Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body surface area for dose calculation","volume":"16","author":"Gurney","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2010.07.015_bib0065","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1200\/JCO.1996.14.9.2590","article-title":"Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative","volume":"14","author":"Gurney","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2010.07.015_bib0070","series-title":"Scientific Pharmacokinetic Library. Rev. A14E","author":"Micromath","year":"1994"},{"key":"10.1016\/j.ejps.2010.07.015_bib0075","first-page":"853","article-title":"The use of body surface area as a criterion of drug dosage in cancer chemotherapy","volume":"18","author":"Pinkel","year":"1958","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2010.07.015_bib0080","unstructured":"Product Information: Adriamycin RDF(R), Adriamycin PFS(R), Doxorubicin, 2000. Pharmacia & Upjohn, Inc., Kalamazoo, MI."},{"key":"10.1016\/j.ejps.2010.07.015_bib0085","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1010639201787","article-title":"Body surface area as a determinant of pharmacokinetics and drug dosing","volume":"19","author":"Sawyer","year":"2001","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejps.2010.07.015_bib0090","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2125.1974.tb00244.x","article-title":"The persistence of adriamycin in man and rat","volume":"1","author":"Wilkinson","year":"1974","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098710002824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098710002824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T08:01:23Z","timestamp":1559376083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098710002824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":18,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0928098710002824"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2010.07.015","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}